Table of Contents

    Topic review

    Mesenteric Fibrosis

    Subjects: Gastroenterology
    View times: 124

    Abstract

    Authors: Anna Koumarianou, Krystallenia I. Alexandraki, Göran Wallin, Gregory Kaltsas and Kosmas Daskalakis.

    Objective: Mesenteric fibrosis (MF) constitutes an underrecognized sequela in patients with small intestinal neuroendocrine neoplasms (SI-NENs), often complicating the disease clinical course. The aim of the present systematic review was to provide an update in evolving aspects of MF pathogenesis and its clinical management in SI-NENs.

    Search strategy: We followed the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) methodology.

    Results: Complex and dynamic interactions are present in the microenvironment of tumor deposits in the mesentery. Serotonin, as well as the signaling pathways of certain growth factors play a pivotal, yet not fully elucidated role in the pathogenesis of MF. Clinically, MF often results in significant morbidity by causing either acute complications, such as intestinal obstruction and/or acute ischemia or more chronic conditions involving abdominal pain, venous stasis, malabsorption and malnutrition.

    Conclusions: Surgical resection in patients with locoregional disease only or symptomatic distant stage disease, as well as palliative minimally invasive interventions in advanced inoperable cases seem clinically meaningful, whereas currently available systemic and/or targeted treatments do not unequivocally affect the development of MF in SI-NENs. Increased awareness and improved understanding of the molecular pathogenesis of MF in SI-NENs may provide better diagnostic and predictive tools for its timely recognition and intervention and also facilitates the development of agents targeting MF.

    1. Introduction

    Small intestinal neuroendocrine neoplasms (SI-NENs) comprise a rare tumor entity with rising incidence, but overall favorable survival outcomes despite frequent presentation at distant stage disease[1]. They originate in enterochromafin (EC) cells, usually in the terminal ileum and less commonly in the jejunum. The primary tumor is typically submucosal and < 1cm in size, whereas in up to 50% of patients multifocal tumors can be found arising independently in the small intestine[2][3]. Mesenteric lymph node (LN) metastases are commonly present at diagnosis and tend to grow conspicuously large and often induce mesenteric fibrosis (MF) in the surrounding tissue of the mesentery.

    The release of various amines, peptides and growth factors (GFs) may induce hormonal symptoms that constitute the carcinoid syndrome (CS), but also fibrosis in cellular systems leading to MF and carcinoid heart disease (CHD)[4][5]. In addition, neuroendocrine neoplasm (NEN) cells overexpress a plethora of proangiogenic molecules that promote both recruitment and proliferation of endothelial cell precursors becoming highly vascularized neoplasms[6].

    Locoregional LN metastases together with the accompanying MF may occur in up to 50% of SI-NENs with encasement of the superior mesenteric vessels at different levels in the mesentery[7][8]. Locoregional resective surgery when feasible constitutes the mainstay of treatment in patients with MF-related symptoms. Although advances in systemic and liver-targeted treatment of SI-NENs have been made, alleviating hormonal symptoms and prolonging progression-free (PFS) and overall survival (OS), effective treatment options targeting MF are not fully elucidated. As improved insight in the complex pathogenesis of MF is key to the development of new therapies, we have reviewed evolving aspects of tumor microenvironment (TME), mediators and signaling pathways involved in the molecular pathogenesis of MF in SI-NENs, in order to refine the management of patients suffering from fibrotic complications.

    2. Experimental Section

    We performed a systematic review of the literature available on PubMed, Cochrane Library, Embase, Web of Science and SCOPUS databases about MF in SI-NENs until March 15th, 2020. Articles were independently evaluated by two of the authors (K.D. and K.I.A.) for the relevance to the planned scope of the review. Reference lists of key publications were also reviewed for eligibility. We followed Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for reporting[9]. The literature search and the selection of included studies are presented in the PRISMA flow diagram (Figure 1).

    Figure 1. Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram of study selection. Abbreviations: ENETS; European Neuroendocrine Tumor Society; NENs: Neuroendocrine Neoplasms.

    3. Results

    3.1. Pathogenesis of Mesenteric Fibrosis (MF)

    In SI-NENs, MF represents an abnormal repair process, mimicking the mechanism operating in certain types of connective tissue disorder, associated with serious complications during the course of the disease[10][11]. Serotonin and vasoactive substances were the first effectors to be implicated in the pathogenesis of CS and into its more severe complications, the MF or CHD, representing the fibrotic-related sequelae of CS. There is currently evidence that CHD pathophysiology is mostly based on circulating effectors, specifically on high serotonin levels as depicted by the high urine level of 5-hydroxyindoleacetic acid (5-HIAA), whereas MF seems to be caused by a complex network of autocrine and paracrine mediators produced by neoplastic cells and TME elements[11].

    TME represents an important functional unit comprising a cluster of endothelial and inflammatory cells and mesenchymal stroma elements with fibroblasts. This network of cells is interconnected and interacting, leading to tumor growth and development of fibrosis, possibly through epigenetic changes of tumor cells[6][12][13]. TME has been recently depicted as a dynamic milieu where an injury with fragmentation of extracellular matrix elements results in chemo-attractant molecules recruiting immune cells that promote a tumorigenic environment, followed by pro-angiogenic elements during tissue repair.

    Proteomic analysis of SI-NENs and associated MF primarily revealed differences in mesenteric stroma showing that certain proteins are involved in the formation and regulation of the extracellular matrix and the complement cascade[14]. In addition, a multitude of immune cells including B and T cells, natural killer (NK) cells, mast cells, dendritic cells and macrophages have been reported to infiltrate NENs, resulting in an immunosuppressed TME, which promotes tumor growth[6]. NEN patients display immune recognition of their tumors, as CD8+ T-cells target specific SI-NEN-associated antigens including chromogranin A and tryptophan hydroxylase[15]. Recently, several studies have addressed the expression of programmed death-ligand 1 (PD-L1) as a potential mechanism of NEN immune evasion, with the upregulation of PD-L1 exhibited in a subset of SI-NENs[16][17][18].

    Importantly, in vitro studies in currently available pancreatic NEN cell lines cannot serve as an ideal model for assessment of MF. However, the development of three-dimensional organoids/spheroids may be a promising model to study the SI-NEN stroma complexity and its influence in epithelial tumorigenesis in the context of MF. Recently, SI-NEN cells have been cultured from surgically removed tumors as spheroids in ECM, forming a three-dimensional matrix that encapsulates SI-NEN cells and mimics TEM[19]. Although, organoid/spheroid systems lack some important components present in vivo, such as fibroblasts, endothelial cells and immune cells, coculture of organoids with other cell types has been attempted in order to generate a more “physiological” TEM, and to study cell–cell interactions with potential future implications in the study of MF[20].

    The effort to understand TME elements sheds light on the paracrine role that GFs may exert, affecting the molecular pathways implicated in fibroblast growth, proliferation and action[12][21]. A number of mediators have been shown to play an essential role in MF pathogenesis (Table 1 and Figure 2).

    Figure 2. Tumor microenvironment represents an important functional unit comprising a cluster of endothelial and inflammatory cells, and mesenchymal stroma elements with fibroblasts interconnected and interacting. An initial event, an injury, induces fragmentation of extracellular matrix elements, chemo-attractant molecules with recruitment of immune cells acting as a pro-tumorigenic environment, followed by pro-angiogenic elements. In specific circumstances, serotonin (5-HT) via a receptor (5-HT Rc) may be mitogenic in stroma cells acting through a TGFβ-mediated mechanism or potentiating the effects of PDGF, β-FGF, or EGF and insulin. TGF-β represents a pro-fibrotic mediator; TGFβ1 and the receptor subtype-2 (TGFβr2) have been identified in SI-NEN. CTGF is transcriptionally activated principally through TGFβ1, acting as a downstream mediator of its profibrotic activities on fibroblasts; PDGF, EGF and FGF are also activating CTGF gene expression at the transcriptional level. PDGF is a mitogen for the fibroblasts and the smooth muscle cells. Infiltration of immune cells is not high in SI-NENS, but tumor-associated macrophages suppress the adaptive immune system and stimulate fibrosis by secretion of profibrotic factors such as TGFβ. Abbreviations: 5-HT: 5-hydroxytryptamine; 5-HT Rc: 5-hydroxytryptamine receptor; TGFβ: transforming growth factor-β; PDGF: platelet-derived growth factor; β-FGF: β-fibroblast growth factor; EGF: Epidermal growth factor; TGFβr2: transforming growth factor-β receptor subtype-2; CTGF: connective tissue growth factor; CAF: cancer-associated fibroblast; GFs: growth factors; IGF-1: insulin growth factor type 1; VEGF: vascular endothelial growth factor; VEGF R: vascular endothelial growth factor receptor; CD8: cluster of differentiation 8; CD4: cluster of differentiation 4; FoxP3: forkhead box P3; Th1: T helper type 1; IFN-α: Interferon alpha.

    3.1.1. Serotonin

    Serotonin (5-hydroxytryptamine; 5-HT) has been classically considered as the main mediator of MF in SI-NENs. However, no consistent association has been documented between MF and elevated serotonin levels[10][22]. Serotonin exhibits both mitogenic and fibrogenic effects in fibroblasts, smooth muscle cells and endothelial cells.

    The strongest evidence that implicates serotonin in the interplay of fibrosis is the finding of higher levels of 5-HIAA in patients with CHD compared to patients without cardiac involvement[23][24][25]. Serotonin administration induces CHD through a transforming growth factor beta (TGFβ)-mediated mechanism[26], and the presence of serotonin likely modulates connective tissue growth factor (CTGF) function. Moreover, serotonin acts in association with other molecules, potentiating the mitogenic activity of the β-fibroblast growth factor (FGF) and the combined action of epidermal growth factor (EGF) and insulin[27].

    Transcript levels and the secretion of TGβ1, CTGF and FGF2 were significantly reduced in SI-NEN treated with a specific 5-HT2B receptor antagonist in vitro[12]. Thus, 5-HT2B receptors and serotonin have an important role in the regulation of peri-tumoral fibrosis and angiogenesis, sustaining TME[12]. In addition, the MEK/extracellular signal-regulated kinase (ERK) pathway is potentially playing a role in this process, since serotonin acts via the G-protein coupled 5-HT receptors, which are activating mitogenic pathways[12].

    Another mechanism for the pathogenesis of MF may be the decreased expression of serotonin-degrading enzymes in the stromal compartment of mesenteric metastases[28]. Recently, the tryptophan metabolism pathway was investigated by label-free proteomics in MF. Quantification of h-5-HT and h-5-HIAA in blood and tissues was simple, highly specific and predictive of steady state changes in 5-HT, opening the possibility for rapid screening of TPH1 inhibitor dose response, such as that of telotristat etiprate[29].

    3.1.2. Growth Factors (GFs)

    GFs act locally by a combination of paracrine and autocrine actions to stimulate cell proliferation and differentiation. Platelet-derived growth factor (PDGF), insulin growth factor 1 (IGF-1) and -2, EGF, TGF-α and TGF-β have shown mitogenic properties on fibroblasts[30].

    Transforming Growth Factor-β (TGF-β)

    TGFβ can stimulate both the production and deposition of the extracellular matrix via increased expression of collagen, fibronectin, proteoglycan and integrin expression in parallel to decreased expression of proteases and increased expression of protease inhibitors[31]. TGFβ is also chemotactic for fibroblasts and macrophages and may induce a rapid local fibrotic response[32]. TGFβ1 and the receptor subtype-2(TGFβrII) have been identified in SI-NEN samples, confirming the interaction of tumor cell with TME to exert its pro-fibrotic role in NENs[33].

    Connective Tissue Growth Factor (CTGF)

    CTGF is involved in the coordination of complex biologic processes such as differentiation, tissue repair and angiogenesis. The low-density lipoprotein (LDL) receptor-related protein/α-2-macroglobulin receptor (LRP2) has been demonstrated to be the receptor for CTGF in fibroblasts[34]. By signaling via integrins, a mechanistic interpretation is provided for the chemotactic and mitogenic properties of CTGF, as well as for its functions in ECM remodeling during angiogenesis and tissue repair[35]. CTGF is transcriptionally activated principally through TGFβ1[36]. However, PDGF, EGF and FGF also activate CTGF gene expression at the transcriptional level[37][38]. Processes such as TGFβ-induced fibroblast proliferation, collagen synthesis and myofibroblast differentiation are regulated by CTGF-dependent pathways. Consequently, CTGF represents a downstream mediator of the profibrotic activities of TGFβ1 acting on fibroblasts, being a mediator of MF in SI-NENs[10][39][40].

    SI-NEN tissues express high CTGF levels[41]. Proteomic and tissue microarray analysis demonstrated that SI-NENs synthesized and secreted CTGF. Serum levels of both CTGF and TGFβ1 were significantly increased in SI-NENs, suggesting that CTGF could be a marker for MF in SI-NENs[41][42]. Overall, TGF-β1 has an autocrine role in SI-NENs besides its paracrine role in MF by inducing CTGF[33]. The CTGF expression pattern is also correlated with the severity of MF.

    All these data suggest that an MF network operates, where the initial event is secretion of TGFβ1, which in turn induces CTGF to act in conjunction, thus leading to the overproduction of collagen after bypassing tissue repair suppression. This network seems to be even more complex since other molecules are possibly participating (Figure 2). In vitro experiments have also demonstrated that the N-terminal region of CTGF stimulates myofibroblast differentiation and collagen production, while the C-terminal stimulates fibroblast cell proliferation[39]. CTGF can be found in SI-NEN patient serum and it is potentially involved in MF[43].

    Platelet-Derived Growth Factor (PDGF)

    SI-NENs express PDGF chains and PDGF receptor types[44]. An autocrine growth may be justified by α-receptors, whereas, tumor cells express B- and A-chains, which may also be synthesized by stromal cells stimulating tumor growth in a paracrine manner[44][45]. PDGF was found to be expressed in tumor cells and stroma in SI-NENs. PDGF α-receptors were found on tumor cells and adjacent stroma, whereas PDGF β -receptors were found only in stroma. Hence, PDGF may be involved in the autocrine stimulation of tumor cells and stimulation of stromal cell growth and matrix deposition.

    Cryosections from SI-NENs showed that the PDGF β-receptor is expressed in 66%, as opposed to 10% of non-NENs tissues respectively. The immunoreaction was present in connective tissue cells adjacent to tumor cell clusters, but not in the tumor cells per se and were more intense in the proximity to the tumor compared to more distant foci[13]. This finding implies that SI-NEN cells may directly or indirectly induce expression of the PDGF-β receptor on adjacent stromal cells in the tumor tissue, which may possibly contribute to the stimulation of connective tissue cell proliferation in SI-NENs[10][13]. However, in one study no detection of PDGFR expression in SI-NENs was reported[46]. In parallel with this, a phase-II study of imatinib, specifically inhibiting the tyrosine kinase domain in PDGFR, showed no substantial regression of SI-NEN, but a significant number of patients with progressive disease achieved disease stabilization[47].

    Insulin-Like Growth Factor 1 (IGF-1)

    Insulin growth factor 1 plays an important role in the physiological regulation of cell growth and differentiation. IGF-1 receptor is present in SI-NEN, suggesting that it may possibly act as an autocrine stimulator of tumor growth[48][39][46]. The recent marker IGF-IEc, an isoform produced by the transcripts of the alternative splicing of the IGF-1 gene has been found to be expressed in SI-NENs[49]. However, since it is in an in vivo SI-NEN model, the serotonin-IGF-1 axis was found to act differentially depending on serotonin levels; hence, more focused studies on MF have yet to be performed[50].

    Epidermal Growth Factor (EGF) and Transforming Growth Factor-a (TGF-α)

    EGF in addition to the transforming growth factor alpha (TGF-α) and -β families of GFs, can stimulate or inhibit proliferation and differentiation in multiple tissues[51]. TGF-α was found to be abundant in tumor cells mediating its effects by binding to the EGF receptor (EGF-R)[30]. TGF-α and EGF receptors are expressed in SI-NENs[30][46], supporting the role of TGF-α in the autocrine regulation of tumor growth[52]. The presence of EGF-R in the stromal component of SI-NENs potentially implies the enhanced role of EGF in the process of MF.

    Other Growth Factors (GFs)

    FGF 2 is a well-known stimulator of vascular endothelial cells and β-FGF is a potent endothelial cell mitogen, playing a crucial role in tumor angiogenesis[12].

    Her2/neu and vascular endothelial growth factor (VEGF)-receptors (VEGF-Rs) were overexpressed in SI-NENs[46]. More recently, it was demonstrated that interleukin-6 (IL-6), VEGF and monocyte chemo-attractant protein 1 (MCP-1) are actively secreted by cancer-associated fibroblasts, to induce tumor cell proliferation[6]. VEGF expression in vitro was modulated by oxygen levels through a pathway regulated by hypoxia-inducible factor 1 (HIF-1α)[53]. In addition, human fibroblasts have been shown to secrete nerve growth factors (NGFs) that have regulatory effects on angiogenesis[48]. In another study, the fibrotic marker vascular adhesion protein-1 (VAP-1) was highly expressed in SI-NEN stroma in close association with the extracellular matrix[54].

    In summary, TME represents an important functional unit comprising a cluster of endothelial and inflammatory cells and mesenchymal stroma elements with fibroblasts interconnected and interacting. Fragmented extracellular matrix elements and chemo-attractant molecules recruit immune cells that act as a pro-tumorigenic environment, interacting with pro-angiogenic elements. In specific circumstances, 5-HT via its receptor may be mitogenic in stroma cells acting through a TGFβ-mediated mechanism or potentiating the effects of PDGF, β-FGF or EGF and insulin. CTGF is transcriptionally activated principally through TGFβ1, acting as a downstream mediator of its profibrotic activities on fibroblasts, whereas PDGF, EGF and FGF are also activating CTGF gene expression at the transcriptional level. Of note, infiltration of immune cells is not high in SI-NENS, but tumor-associated macrophages may display a tumor-promoting role whilst they suppress the adaptive immune system and stimulate fibrosis by secretion of profibrotic factors such as TGFβ (Figure 2).

    3.2. Clinical Presentation

    3.2.1.Symptoms and Related Deficiencies

    Patients with SI-NENs are rarely diagnosed before locoregional LN metastases have developed, and often present with advanced symptomatic disease. In this setting, the disease clinical manifestations are most commonly due to MF around locoregional tumor deposits. MF can cause contraction and tethering of the adjacent bowel loop leading to acute symptoms, such as intestinal obstruction, intussusception and/or intestinal ischemia by impaired blood supply to the intestines[55][56]. The presence of advanced MF associated with intestinal ischemia has been recently identified as a poor prognostic factor for OS[5]. Venous ischemia due to superior mesenteric vein involvement is more often encountered as compared to its arterial counterpart, resulting in venous stasis, abdominal pain, aggravated diarrhea, ascites, malabsorption and malnutrition[57]. In advanced cases, MF surrounding LN metastases in the root of the mesentery may lead to shrinkage and fixation of it to the retroperitoneum that can cause in turn obstruction of the small intestine, duodenum and/or transverse colon. Chyloabdomen may also occur in patients with advanced MF owing to lymphatic obstruction. Occasionally, CS may accompany MF with retroperitoneal extension, when tumor secretory products exceed the detoxifying capacity of the liver, or bypass it, draining directly into the systemic circulation through retroperitoneal lymphatic spread[4][5][55][58]. Extensive retroperitoneal fibrosis may be complicated with obstructive uropathy, hydronephrosis and renal failure late in the disease clinical course[5]. Moreover, involvement of the vasculature in the root of the mesentery may result in collaterals that could predispose for lower gastrointestinal hemorrhages.

    Apart from acute symptoms, MF can cause partial bowel obstruction and chronic postprandial abdominal pain, influencing patients’ food intake and nutritional status in the long term. In addition, profound diarrhea due to refractory CS, but also due to venous stasis and malabsorption in cases with extensive MF may induce nutritional deficiencies and quality of life impairment. As part of malnutrition in this setting, there are often encountered deficiencies in fat-soluble vitamins, mainly vitamin D, whereas severe disturbances in water and electrolyte homeostasis may also occur[59]. Moreover, in patients with CS, up to 60% of tryptophan is used for serotonin production leading to tryptophan deficiency and subsequently lower niacin levels and sometimes pellagra in a subset of patients[59][60][61]. However, although malnutrition in cancer patients can result in low levels of trace elements like cobalt, copper, fluorine, iodine, selenium and zinc, little is known about trace elements’ deficiencies owing to aggravated diarrhea related to MF in patients with SI-NENs[59].

    3.3. Diagnostic and Classification Systems

    The presence of MF is radiologically defined as enhancing spiculated soft-tissue mass with fibrotic bands radiating outward in the mesenteric fat in a stellate pattern around an LN metastasis on cross-sectional imaging[56][62](Figure 3). The radiological severity of MF is based on the following classification: (a) no radiological evidence of MF (absence of radiating strands), (b) mild MF (≤ 10 thin radiating strands), (c) moderate MF (> 10 thin strands or < 10 thick strands) and (d) severe MF (≥ 10 thick strands)[62]. Of note, the radiological severity described by Pantograg—Brown is not correlated with any kind of clinical aspects such as symptoms or prognosis[62]. The histological assessment of MF is based on the histological section of the surgical specimen with the maximum amount of fibrous tissue. The mesenteric LN metastasis and surrounding tissue are examined for MF using Sirius Red staining and the width of the thickest fibrous band surrounding the tumor is measured.

    Figure 3. Presence of mesenteric fibrosis in a patient with a small intestinal neuroendocrine tumor as an enhancing soft-tissue mass with fibrotic bands radiating outward in the mesenteric fat in a stellate pattern around a lymph node metastasis in coronary and transverse planes.

    Importantly, the extension of mesenteric LN metastases and associated MF below or above the horizontal part of the duodenum is a crucial factor for surgical planning[63]. An arbitrary staging system of the mesenteric LN metastases and accompanying MF has been developed by the Uppsala group (Stage I: LN metastases close to the intestine; Stage II: LN metastases higher in the mesentery; Stage III: LN metastases along, but not encasing the mesenteric vessels at the level of the horizontal duodenum; Stage IV: LN metastases extending above the horizontal part of the duodenum, encasing the superior mesenteric vessels)[8]. However, the validity of this system and its effect on surgical management of SI-NEN patients has not been established to date.

    Notably, when utilizing histopathological, surgical and radiological correlations, computed tomography (CT) imaging has limitations and may underestimate the presence of MF[64][65]. This needs to be considered when making clinical decisions regarding the management of these patients in view of the considerable morbidity associated with MF. Importantly, as most SI-NENs express somatostatin receptors on the cell surfaces, functional imaging with somatostatin receptor-based Gallium-68 positron emission tomography–computed tomography (68Ga–PET–CT) has been shown to detect more primary SI-NENs and also metastatic tumor deposits, including peritoneal carcinomatosis lesions frequently encountered in the proximity of advanced MF, as compared to conventional contrast-enhanced CT[5][66]. Therefore, functional imaging with 68Ga-PET–CT may have a role in the accurate detection and staging of lymph node metastases surrounded by MF with important implications in surgical planning. On the other hand, fluorine-18 ((18)F)-fluorodeoxyglucose ((18)F-FDG) PET may be of limited value in low-proliferative well-differentiated SI-NENs. However, it could be particularly helpful for visualizing a subset of more aggressive SI-NENs, such as well-differentiated tumors with Ki67 values > 10%. According to limited data, (18)F-FDG-avid tumor lesions, even in slow-growing NENs, may indicate a more aggressive biological behavior[67]. Nevertheless, as available pathology data from SI-NEN patients with MF fibrosis have confirmed fibrotic reactions in close proximity to mesenteric LN metastases[5], molecular imaging studies along with conventional cross-sectional imaging can be used to delineate the management of complex cases with MF.

    When considering the imaging modalities used in other fibrotic conditions, such as liver fibrosis, current cross-sectional and functional methods of evaluating its extent often provide an incomplete picture, whereas certain methods such as ultrasonography and elastography are not applicable in the setting of MF. A novel PET tracer has recently been proposed in a preclinical study demonstrating that imaging hepatic integrin αvβ3 with PET and (18F)-Alfatide may offer a non-invasive method for monitoring the progression of liver fibrosis[68].

    With respect to diagnostic biomarkers for MF, only a few studies have assessed the utility of non-invasive monoanalyte biomarkers (serum CTGF and urinary 5-HIAA) in this setting[43][69][70].

    However, these markers perform modestly and have not been specifically applied in the clinical practice for the assessment of MF as yet. Recently, a set of five profibrotic circulating transcripts with known roles in fibrosis (CTGF, CD59, amyloid precursor-like protein 2 (APLP2), frizzled homologue (FZD) 7 and BCL2/adenovirus E1B 19 kDa protein-interacting protein 3-like (BNIP3L)), taking the name of “fibrosome” has been assessed[65]. The combination of these five circulating transcripts (from the entire 51-gene molecular signature of the NETest) has demonstrated an accuracy of 100% for the detection of microscopic MF and a higher accuracy, as compared to radiological and surgical assessments. Given the ability of the multianalyte NETest to act as a liquid biopsy that can capture the multidimensionality of NEN, the “fibrosome” set appears to be a promising biomarker for MF detection[65]. However, further validation of these results is warranted in prospective studies.

    3.4. Clinical Management of Mesenteric Fibrosis

    3.4.1. Surgical Management

    Importantly, the mainstay of treatment for MF in SI-NEN patients is locoregional resective surgery either with a curative intent or to provide symptomatic relief, depending on the stage of the disease (Figure 4)[71]. However, compromise of the mesenteric vasculature in the root of the mesentery may render surgical resection technically challenging and endanger the circulation to substantial parts of the intestine, leading to devastating complications such as short-bowel syndrome. Nevertheless, radical resection is not always possible due to the location of large metastatic LN conglomerates and the encasement of the superior mesenteric vessels in the root of the mesentery[5][63]. The National Comprehensive Cancer Network Guidelines on SI-NENs advocate against the resection of a small, asymptomatic, relatively stable primary tumor in the presence of unresectable metastatic disease. A recent study has confirmed no OS benefit in asymptomatic patients with distant-stage disease who underwent upfront locoregional resective surgery, however radiological assessment of MF was not included[72]. These results are also consistent with the findings of two recent cohort studies of SI-NEN patients with MF that confirmed no survival benefit of locoregional resective surgery in the presence of MF in asymptomatic patients with stage IV disease[69][73]. However, a further study has revealed that the presence of MF is linked with a more aggressive biological behavior when PFS was used as a surrogate endpoint, despite similar Ki-67 labelling indices[74]. In addition, size and morphologic features of mesenteric tumor deposits appear to have no prognostic impact; instead, deposit multifocality may be associated with patient outcomes, whereas the extent of bowel resection seems to be associated with the extent of MF[75][76]. A significant association of MF with metastatic patterns and with criteria of functionality has been confirmed, suggesting a common pathophysiological mechanism[70]. It should be noticed though that while asymptomatic patients with MF and disseminated, SI-NENs may not benefit from up-front prophylactic surgery; some patient populations might, such as older patients and patients with progressive loco-regional disease[77]. Importantly, in order to be able to identify patients who might benefit from a prophylactic surgical approach, more insight is needed into the development of MF in SI-NENs[78]. Of note, multivisceral transplantation including the small intestine is a seldom-utilized approach worldwide for highly selected patients with extensive metastatic burden, i.e., potentially some SI-NEN patients with no liver metastases but extensive metastatic disease in the root of the mesentery and associated MF threatening a vascular catastrophe of the gut by encasement of mesenteric vessels[79].

    Figure 4. Management of Small Intestinal NENs with Mesenteric Fibrosis-Flow diagram. † Systemic treatment recommendations adapted from ESMO 2020 Clinical Practice Guidelines for diagnosis, treatment and follow-up of Gastroenteropancreatic Neuroendocrine Neoplasms[80]. Abbreviations. BSC: best supportive care; CAP: capecitabin; CS: carcinoid syndrome; FOLFOX: Folinic acid, Fluorouracil (5-FU) and Oxaliplatin; IF-a: interferon alpha; MF: mesenteric fibrosis; MWA: microwave ablation; NP: nephropyelostomy; PD: progressive disease; PRRT: Peptide Receptor Radionuclide Therapy; RE: radio-embolization; RF: Radiofrequency ablation; TACE: trans-arterial chemo-embolization; SMV: superior mesenteric vein; SSA: somatostatin analogue; SSTR: somatostatin receptor; TAE: trans-arterial embolization; TE: telotristat etiprate; TEM: temozolomide; WD-SINENs: well-differentiated small intestinal neuroendocrine neoplasms.

    Minimal Invasive Management

    SI-NEN patients with an advanced degree of arterial and venous involvement in the root of the mesentery and in the presence of extensive MF are unlikely to receive radical locoregional surgery and should therefore be spared unnecessary laparotomies if asymptomatic[75]. Interestingly, prolonged OS has been demonstrated after minimal invasive interventions in patients with inoperable locoregional disease due to MF, as compared to those with no intervention and a similar stage IV tumor burden[5]. Transhepatic endoluminal stenting of the superior mesenteric vein appears to be a relatively safe procedure that may be undertaken in cases with advanced inoperable disease and severe ischemic symptoms resistant to conservative medical control[5][81]. Stent failure is most likely attributed to thrombosis and the role of anticoagulation in this setting remains to be defined in further studies with longer follow-up[80]. Other minimal invasive measures with palliative purposes in order to preserve renal function in advanced stages may include intra-ureteral J-stent and percutaneous nephrostomy for the management of obstructive uropathy due to advanced SI-NEN-related retroperitoneal fibrosis[5].

    3.4.2. Medical Treatment

    Somatostatin Analogues (SSAs)

    The CLARINET and PROMID trials have shown that long-term treatment with long-acting somatostatin analogues (SSAs), lanreotide autogel and octreotide slow release, may exert an anti-tumor activity on SI-NENs[82][83]. Treatment with SSAs designed to reduce circulating tumor metabolites (including 5-HT), has been shown to achieve symptomatic and antitumoral response and may confer the additional advantage of retarding or preventing the progression of CHD[84]. In addition, assessment of the level of serum fibrosis markers CTGF and TGFβ in patients with CS treated with prolonged-release SSAs revealed a reduction of CTGF and TGFβ levels, which could in turn prevent the formation of MF[85]. This study confirmed other preclinical ones exhibiting a potential inhibitory effect of SSAs in local fibrosis formation by reducing the secretion of profibrotic growth factors such as TGFβ[86][87]. Despite the control of CS, including normalization of serotonin secretion and reduction of bioactive peptides, the effect of SSAs in MF remains to be determined prospectively in further studies.

    Serotonin Synthesis Inhibitors and 5-HT Receptor Antagonists

    As the FGF pathway is highly activated in SI-NENs with CS owing to elevated serotonin, it has been implied that therapies that inhibit serotonin synthesis may prevent CHD and MF[55][88]. Efficacy of telotristat ethyl, a novel agent inhibiting peripheral serotonin synthesis was assessed in two phase III clinical trials: TELESTAR and TELECAST[89][90]. This prodrug is converted into its active metabolite: telotristat etiprate that inhibits tryptophan function, resulting in a reduction of the serotonin bloodstream levels[91]. The TELESTAR trial reported a reduction in diarrhea in those patients treated with telotristat ethyl together with a significant reduction of urinary 5-HIAA levels[89]. The TELECAST study provided further confirmation about the efficacy and the safety of telotristat ethyl[90]. With respect to the impact of telotristat ethyl on fibrosis, two of the patients recruited into the TELESTAR trial with known CHD had stable valvular function on follow-up[91][92]. However, no evidence of antitumor effect or impact of telotristat ethyl on MF is available as yet.

    Apart from inhibition of 5-HTsynthesis, 5-HT receptor antagonists may target serotonin signaling and potentially reduce MF in SI-NENs. The 5HT2 antagonists ketanserin and cyproheptadine have been found to inhibit attacks of flushing, diarrhea and dyspnea in patients with CS[93][94]. Their therapeutic benefit would appear to be a peripheral effect, as 5-HIAA excretion in these patients was not reduced[94]. Another 5-HT receptor antagonist, terguride, reduces the pro-fibrotic potential in scleroderma and suppresses pathways implicated in the regulation of pro-fibrotic genes, suggesting that 5-HT inhibitors might reduce MF via suppression of TGF-β1-mediated non-canonical signaling pathways[95]. Therefore, serotonin synthesis antagonists and 5-HT receptor inhibitors may have an important role not only in the management of severe CS, but also in the prevention of MF, pending confirmation of prospective clinical studies in SI-NENs.

    Molecular Targeted Therapies (mTOR and Tyrosine Kinase Inhibitors)

    The phase III RADIANT-4 trial reported that everolimus significantly improved PFS in patients with progressive SI-NENs[96]. However, the response to treatment is not durable, most likely due to incomplete and unsustained inhibition of mTORC1 signaling by this compound, and/or activation of mTOR complex 2 (mTORC2), underscoring the need for alternative therapies and drug combinations. In a recent preclinical study, in vitro mTOR kinase inhibition effectively stabilized progressive NENs and delayed cardiac impairment[97]. mTOR inhibition may result in a decrease of the expression of 5-HT receptors, as well as that of other players that may be implicated in fibrosis development: however, the exact mechanisms underlying mTOR inhibition’s impact on MF are currently unknown[97][98].

    SI-NEN proliferation is responsive to a number of GFs, such as EGF, PDGF, TGFα, TGFβ and CTGF, and therefore may be susceptible to tyrosine kinase inhibitors (TKIs) targeting these receptors or associated signaling pathways[99][100][101]. In particular, TGFα stimulation can be inhibited at several points of the MAPK pathway, but success is limited to NEN models and is not evident in the clinical setting. In addition, although some NENs are inhibited by TGFβ1, paradoxical growth has been seen in experimental models of SI-NENs[100]. CTGF expression is associated with more malignant clinical phenotypes, as it promotes growth in SI-NEN models, and is implicated as a mediator of local and distant fibrosis. However, the anti-proliferative effect of CTGF inhibition has not been tested in NENs[100]. Notably, although TKIs have not gained approval and their efficacy seems limited in SI-NENs; their impact on MF and CHD have not been specifically addressed[102][103]. Contemporary research on fibrotic diseases focuses on promising TKIs, such as imatinib-targeting c-alb kinases and PDGF receptors[104][105]. The multiple and overlapping signaling pathways that characterize SI-NENs suggest targeting these tumors at a number of levels may be required to provide efficacy[100]. Although the studies assessing the efficacy of TKIs in SI-NENs did not focus on MF, the molecular pathways involved in its development are similar between SI-NENs and other fibrotic conditions that TKIs can target. Thus, the use of TKIs in SI-NENs could be extended beyond their anti-tumor effects and also be evaluated in the context of prevention or reversal of MF.

    Peptide Receptor Radionuclide Therapy (PRRT)

    The efficacy of PRRT in the management of SI-NENs has been confirmed in the NETTER-1 trial[106]. The delivery of targeted PRRT locoregionally in the mesenteric LN conglomerate could be associated with a risk of inducing a local reaction, hence increasing the risk of MF-related complications. In a recent study investigating this, the severity of MF did not seem to be affected after PRRT[107].

    Other Antifibrotic Agents

    Angiotensin-converting-enzyme (ACE) inhibitors through renin–angiotensin system inhibition may reduce tumor progression and potentially affect SI-NEN-related MF[108]. Ex vivo angiotensin-converting enzyme (ACE) inhibition has been shown to reduce BON1 cell proliferation, but further in vivo and human studies are needed to address ACE inhibitors’ clinical efficacy in patients with SI-NENs[32]. In addition, tamoxifen has been used in SI-NENs in the 1980s for control of CS and also for that of tumoral growth[109][110][111][112]. More recently, it has been used in other fibrotic diseases, however its clinical value in MF, probably mediated by TGFβ inhibition, has not been determined as yet[113][114].

    4. Conclusions

    SI-NENs are often associated with the development of locoregional fibrotic reactions in the mesentery that may lead to severe symptomatology with significant associated morbidity. Locoregional resective surgery remains the mainstay of treatment in symptomatic cases of all stages, however its survival benefit in asymptomatic patients with disseminated disease has been recently challenged. Moreover, in inoperable cases, prompt recognition of MF-related complications and minimally invasive interventions as clinically indicated per patient seem effective in disease palliation. As the impact of modern multimodality systemic and/or targeted treatments in SI-NEN-related MF has not been adequately investigated, elucidation of the molecular basis of MF in this setting may guide our ability to develop predictive biomarkers as well as targeted drug therapies for the prevention or reversal of MF. Three-dimensional organoids/spheroids and coculture of these with other cell types may be a promising model for several translational applications that may facilitate the study of NEN stroma complexity and its influence in epithelial tumorigenesis in the context of MF. In addition, the investigation of epigenetic changes in SI-NEN as a driver of MF and the clinical utility of profibrotic circulating transcripts as a novel biomarker for MF stratification should be assessed in further studies. Finally, composite endpoints in SI-NEN future clinical studies, such as health-related quality of life, symptom-specific survival or development of symptoms specifically owing to growing mesenteric LN metastases and/or increasing MF may be more valid than OS and PFS as endpoints when assessing the effects of SINEN-related MF. Although the antitumor efficacy of TKIs and 5-HT synthesis inhibitors and receptor antagonists in SI-NENs may be limited or may not have been fully determined respectively, further studies on these drugs and other novel agents targeting MF are warranted to guide the development of medical treatments that would reduce MF and alleviate associated symptoms.

    The entry is from 10.3390/jcm9061777

    References

    1. Arvind Dasari; Chan Shen; Daniel M Halperin; Bo Zhao; Shouhao Zhou; Ying Xu; Tina Shih; James C. Yao; Trends in the Incidence, Prevalence, and Survival Outcomes in Patients With Neuroendocrine Tumors in the United States.. JAMA Oncology 2017, 3, 1335-1342, 10.1001/jamaoncol.2017.0589.
    2. Eriksson, J.; Norlen, O.; Ogren, M.; Garmo, H.; Ihre-Lundgren, C.; Hellman, P. Primary small intestinal neuroendocrine tumors are highly prevalent and often multiple before metastatic disease develops. Scand. J. Surg. 2019.
    3. Zhang, Z.; Makinen, N.; Kasai, Y.; Kim, G.E.; Diosdado, B.; Nakakura, E.; Meyerson, M. Patterns of chromosome 18 loss of heterozygosity in multifocal ileal neuroendocrine tumors. Genes Chromosomes Cancer 2020.
    4. Modlin, I.M.; Oberg, K.; Chung, D.C.; Jensen, R.T.; de Herder, W.W.; Thakker, R.V.; Caplin, M.; Delle Fave, G.; Kaltsas, G.A.; Krenning, E.P.; et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol. 2008, 9, 61–72.
    5. Daskalakis, K.; Karakatsanis, A.; Stalberg, P.; Norlen, O.; Hellman, P. Clinical signs of fibrosis in small intestinal neuroendocrine tumours. Br. J. Surg. 2017, 104, 69–75.
    6. Mauro Cives; Eleonora Pelle'; Davide Quaresmini; Francesca Maria Rizzo; Marco Tucci; Franco Silvestris; The Tumor Microenvironment in Neuroendocrine Tumors: Biology and Therapeutic Implications. Neuroendocrinology 2019, 109, 83-99, 10.1159/000497355.
    7. Druce, M.R.; Bharwani, N.; Akker, S.A.; Drake, W.M.; Rockall, A.; Grossman, A.B. Intra-abdominal fibrosis in a recent cohort of patients with neuroendocrine (‘carcinoid’) tumours of the small bowel. QJM Mon. J. Assoc. Physicians 2010, 103, 177–185.
    8. Ohrvall, U.; Eriksson, B.; Juhlin, C.; Karacagil, S.; Rastad, J.; Hellman, P.; Akerstrom, G. Method for dissection of mesenteric metastases in mid-gut carcinoid tumors. World J. Surg. 2000, 24, 1402–1408.
    9. David Moher; Alessandro Liberati; Jennifer Tetzlaff; Douglas G. Altman; Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. Annals of Internal Medicine 2009, 151, 264-269, 10.7326/0003-4819-151-4-200908180-00135.
    10. Shapiro, M.; Kidd, M.; Lye, K.D.; Usinger, W.; Murren, J.; Modlin, I.M. Ileal carcinoids over-express the fibrosis-related peptide, CTGF. Gastroenterology 2004, 126, 505.
    11. Modlin, I.M.; Shapiro, M.D.; Kidd, M. Carcinoid tumors and fibrosis: An association with no explanation. Am. J. Gastroenterol. 2004, 99, 2466–2478.
    12. Svejda, B.; Kidd, M.; Giovinazzo, F.; Eltawil, K.; Gustafsson, B.I.; Pfragner, R.; Modlin, I.M. The 5-HT(2B) receptor plays a key regulatory role in both neuroendocrine tumor cell proliferation and the modulation of the fibroblast component of the neoplastic microenvironment. Cancer 2010, 116, 2902–2912.
    13. Funa, K.; Papanicolaou, V.; Juhlin, C.; Rastad, J.; Akerstrom, G.; Heldin, C.H.; Oberg, K. Expression of platelet-derived growth factor beta-receptors on stromal tissue cells in human carcinoid tumors. Cancer Res. 1990, 50, 748–753.
    14. Blazevic, A.; Iyer, A.; Van Velthuysen, M.L.F.; Feelders, R.A.; Franssen, G.J.H.; Zajec, M.; Hofland, J.; Luider, T.M.; De Herder, W.W.; Hofland, L.J. Proteomic analysis of small intestinal neuroendocrine tumours and associated mesenteric fibrosis reveals primarily differences in mesenteric stroma. In Proceedings of the ENETS 2019, Barcelona, Spain, 6–8 March 2019.
    15. Sofia Vikman; R. Sommaggio; Manuel De La Torre; Kjell Öberg; M Essand; Valeria Giandomenico; Angelica Loskog; Thomas H. Totterman; Midgut carcinoid patients display increased numbers of regulatory T cells in peripheral blood with infiltration into tumor tissue.. Acta Oncologica 2009, 48, 391-400, 10.1080/02841860802438495.
    16. Lamarca, A.; Nonaka, D.; Breitwieser, W.; Ashton, G.; Barriuso, J.; McNamara, M.G.; Moghadam, S.; Rogan, J.; Mansoor, W.; Hubner, R.A.; et al. PD-L1 expression and presence of TILs in small intestinal neuroendocrine tumours. Oncotarget 2018, 9, 14922–14938.
    17. Kim, S.T.; Ha, S.Y.; Lee, S.; Ahn, S.; Lee, J.; Park, S.H.; Park, J.O.; Lim, H.Y.; Kang, W.K.; Kim, K.M.; et al. The impact of PD-L1 expression in patients with metastatic GEP-NETs. J. Cancer 2016, 7, 484–489.
    18. Sampedro-Nunez, M.; Serrano-Somavilla, A.; Adrados, M.; Cameselle-Teijeiro, J.M.; Blanco-Carrera, C.; Cabezas-Agricola, J.M.; Martinez-Hernandez, R.; Martin-Perez, E.; Munoz de Nova, J.L.; Diaz, J.A.; et al. Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors. Sci. Rep. 2018, 8, 17812.
    19. Po Hien Ear; Guiying Li; Meng Wu; Ellen Abusada; Andrew M. Bellizzi; James R. Howe; Establishment and Characterization of Small Bowel Neuroendocrine Tumor Spheroids.. Journal of Visualized Experiments 2019, null, e60303, 10.3791/60303.
    20. Giulia Bresciani; Leo J. Hofland; Fadime Dogan; Georgios Giamas; Teresa Gagliano; Maria Chiara Zatelli; Evaluation of Spheroid 3D Culture Methods to Study a Pancreatic Neuroendocrine Neoplasm Cell Line. Frontiers in Endocrinology 2019, 10, 682, 10.3389/fendo.2019.00682.
    21. Léon C.L. Van Kempen; The tumor microenvironment: a critical determinant of neoplastic evolution. European Journal of Cell Biology 2003, 82, 539-548, 10.1078/0171-9335-00346.
    22. P. P. Anthony; R. A. B. Drury; Elastic vascular sclerosis of mesenteric blood vessels in argentaffin carcinoma. Journal of Clinical Pathology 1970, 23, 110-118, .
    23. Denney, W.D.; Kemp, W.E., Jr.; Anthony, L.B.; Oates, J.A.; Byrd, B.F., 3rd. Echocardiographic and biochemical evaluation of the development and progression of carcinoid heart disease. J. Am. Coll. Cardiol. 1998, 32, 1017–1022.
    24. Robiolio, P.A.; Rigolin, V.H.; Wilson, J.S.; Harrison, J.K.; Sanders, L.L.; Bashore, T.M.; Feldman, J.M. Carcinoid heart disease. Correlation of high serotonin levels with valvular abnormalities detected by cardiac catheterization and echocardiography. Circulation 1995, 92, 790–795.
    25. Zuetenhorst, J.M.; Bonfrer, J.M.; Korse, C.M.; Bakker, R.; van Tinteren, H.; Taal, B.G. Carcinoid heart disease: The role of urinary 5-hydroxyindoleacetic acid excretion and plasma levels of atrial natriuretic peptide, transforming growth factor-beta and fibroblast growth factor. Cancer 2003, 97, 1609–1615.
    26. Björn I. Gustafsson; Karin Tømmerås; Ivar Nordrum; Jan P. Loennechen; Anders Brunsvik; Erik Solligård; Reidar Fossmark; Ingunn Bakke; Unni Syversen; Helge Waldum; et al. Long-Term Serotonin Administration Induces Heart Valve Disease in Rats. Circulation 2005, 111, 1517-1522, 10.1161/01.cir.0000159356.42064.48.
    27. M Spatz; PATHOGENETIC STUDIES OF EXPERIMENTALLY INDUCED HEART LESIONS AND THEIR RELATION TO THE CARCINOID SYNDROME.. Laboratory Investigation 1964, 13, 288-300, .
    28. Blazevic, A.; Lyer, A.; Van Velthuysen, M.L.F.; Hofland, J.; Franssen, G.J.H.; Feelders, R.A.; Zajec, M.; Luider, T.M.; De Herder, W.W.; Hofland, L.J. Aberrant tryptophan metabolism in stromal cells is associated with mesenteric fibrosis in small intestinal neuroendocrine tumours. In Proceedings of the 17th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain, 11–13 March 2020; p. 56.
    29. Richard W. D. Welford; Magali Vercauteren; Annette Trébaul; Christophe Cattaneo; Doriane Eckert; Marco Garzotti; Patrick Sieber; Jérôme Segrestaa; Rolf Studer; Peter M. A. Groenen; et al. Serotonin biosynthesis as a predictive marker of serotonin pharmacodynamics and disease-induced dysregulation. Scientific Reports 2016, 6, 30059, 10.1038/srep30059.
    30. Ola Nilsson; Bo Wängberg; Amanda McRae; Annica Dahlström; Håkan Ahlman; Growth Factors and Carcinoid Tumours. Acta Oncologica 1993, 32, 115-124, 10.3109/02841869309083899.
    31. R A Ignotz; J Massagué; Transforming growth factor-beta stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix.. Journal of Biological Chemistry 1986, 261, 4337–4345. , .
    32. R D Beauchamp; R J Coffey; R M Lyons; E A Perkett; C M Townsend; H L Moses; Human carcinoid cell production of paracrine growth factors that can stimulate fibroblast and endothelial cell growth.. Cancer Research 1991, 51, 5253–5260, .
    33. A Wimmel; B Wiedenmann; Stefan Rosewicz; Autocrine growth inhibition by transforming growth factor β-1 (TGFβ-1) in human neuroendocrine tumour cells. Gut 2003, 52, 1308-1316, .
    34. Joseph M. Schober; Ningyu Chen; Tatiana M. Grzeszkiewicz; Igor Jovanovic; Eugene E. Emeson; Tatiana P. Ugarova; Richard D. Ye; Lester F. Lau; Stephen C.-T. Lam; Identification of integrin αMβ2 as an adhesion receptor on peripheral blood monocytes for Cyr61 (CCN1) and connective tissue growth factor (CCN2): immediate-early gene products expressed in atherosclerotic lesions. Blood 2002, 99, 4457-4465, 10.1182/blood.v99.12.4457.
    35. Ingrid E Blom; R Goldschmeding; Andrew Leask; Gene regulation of connective tissue growth factor: new targets for antifibrotic therapy?. Matrix Biology 2002, 21, 473-482, 10.1016/s0945-053x(02)00055-0.
    36. G R Grotendorst; H Okochi; N Hayashi; A novel transforming growth factor beta response element controls the expression of the connective tissue growth factor gene.. Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research 1996, 7, 469–480, .
    37. Essam El-Din A. Moussad; David R. Brigstock; Connective Tissue Growth Factor: What's in a Name?. Molecular Genetics and Metabolism 2000, 71, 276-292, 10.1006/mgme.2000.3059.
    38. D. R. Brigstock; The Connective Tissue Growth Factor/Cysteine- Rich 61/Nephroblastoma Overexpressed (CCN) Family. Endocrine Reviews 1999, 20, 189-206, 10.1210/er.20.2.189.
    39. Gregory A Kaltsas; Janet Cunningham; Sture E Falkmer; Lars Grimelius; Apostolos V Tsolakis; Expression of connective tissue growth factor and IGF1 in normal and neoplastic gastrointestinal neuroendocrine cells and their clinico-pathological significance. Endocrine-Related Cancer 2010, 18, 61-71, 10.1677/erc-10-0026.
    40. Janet L. Cunningham; Apostolos V Tsolakis; Annica Jacobson; E. T. Janson; Connective tissue growth factor expression in endocrine tumors is associated with high stromal expression of α-smooth muscle actin. European Journal of Endocrinology 2010, 163, 691-697, 10.1530/eje-10-0420.
    41. Michael D. Shapiro; Sam Hanon; Carconoid heart disease arising from an ovarian teratoma. International Journal of Cardiology 2005, 104, 115-118, 10.1016/j.ijcard.2005.01.048.
    42. Shinichi Sato; T Nagaoka; M Hasegawa; T Tamatani; T Nakanishi; M Takigawa; K Takehara; Serum levels of connective tissue growth factor are elevated in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis.. The Journal of Rheumatology 2000, 27, 149–154, .
    43. M Kidd; Irvin Modlin; Shapiro; Rl Camp; Sm Mane; W Usinger; Jr Murren; CTGF, intestinal stellate cells and carcinoid fibrogenesis. World Journal of Gastroenterology 2007, 13, 5208-5216, 10.3748/wjg.v13.i39.5208.
    44. A Chaudhry; V Papanicolaou; K Oberg; C H Heldin; K Funa; Expression of platelet-derived growth factor and its receptors in neuroendocrine tumors of the digestive system.. Cancer Research 1992, 52, 1006-1012, .
    45. Arvind Chaudhry; Keiko Funa; Kjell Öberg; Expression of Growth Factor Peptides and Their Receptors in Neuroendocrine Tumors of the Digestive System. Acta Oncologica 1993, 32, 107-114, 10.3109/02841869309083898.
    46. Kanika A. Bowen; Scott R. Silva; Taylor S. Riall; Hung Q. Doan; B.M. Evers; 811 Population-Based Analysis and Growth Factor Receptor Expression of GI Carcinoid Tumors. Gastroenterology 2009, 136, A880, 10.1016/s0016-5085(09)64065-8.
    47. James C Yao; Jun X. Zhang; Asif Rashid; S.-C. J. Yeung; Janio Szklaruk; K R Hess; Keping Xie; Lee Ellis; James L. Abbruzzese; Jaffer A. Ajani; et al. Clinical and In vitro Studies of Imatinib in Advanced Carcinoid Tumors. Clinical Cancer Research 2007, 13, 234-240, 10.1158/1078-0432.ccr-06-1618.
    48. Paul J Zhang; Emma E Furth; X Cai; John R Goldblum; Therisa L Pasha; K.W Min; The role of β-catenin, TGFβ3, NGF2, FGF2, IGFR2, and BMP4 in the pathogenesis of mesenteric sclerosis and angiopathy in midgut carcinoids. Human Pathology 2004, 35, 670-674, 10.1016/j.humpath.2003.12.010.
    49. Krystallenia Alexandraki; Anastassios Philippou; Georgios Boutzios; Irini Theohari; Michael Koutsilieris; Ioanna Kassiani Delladetsima; Gregory A. Kaltsas; IGF-IEc expression is increased in secondary compared to primary foci in neuroendocrine neoplasms. Oncotarget 2017, 8, 79003-79011, 10.18632/oncotarget.20743.
    50. Bernhard Svejda; Mark Kidd; Andrew Timberlake; Kathy Harry; Alexander Kazberouk; Simon Schimmack; Ben Lawrence; Roswitha Pfragner; Irvin M. Modlin; Serotonin and the 5-HT7 receptor: The link between hepatocytes, IGF-1 and small intestinal neuroendocrine tumors. Cancer Science 2013, 104, 844-855, 10.1111/cas.12174.
    51. C M Stoscheck; L E King; Role of epidermal growth factor in carcinogenesis.. Cancer Research 1986, 46, 1030-1037, .
    52. Chaudhry, A.; Oberg, K.; Transforming Growth Factor-Alpha and Epithelial Growth Factor Receptor Expression in Neuroendocrine Tumors of the Digestive System. Diagn. Oncol. 1993, 3, 81–85, .
    53. Martin Haugen; Rikard Dammen; Bernhard Svejda; Bjorn I. Gustafsson; Roswitha Pfragner; Irvin Modlin; Mark Kidd; Differential signal pathway activation and 5-HT function: the role of gut enterochromaffin cells as oxygen sensors.. American Journal of Physiology-Gastrointestinal and Liver Physiology 2012, 303, G1164-G1173, 10.1152/ajpgi.00027.2012.
    54. Sagar, V.M.; Neil, D.A.; Papakyriacou, P.; Shah, T.; Liu, B.; Hirschfield, G.; Steeds, R.P.; Shetty, S.; Weston, C.J. The proinflammatory molecule, VAP-1, is enriched in the stroma of midgut NETs and plaques of carcinoid heart disease valves. In Proceedings of the 17th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, Barcelona, Spain, 11–13 March 2020.
    55. Druce, M.; Rockall, A.; Grossman, A.B. Fibrosis and carcinoid syndrome: From causation to future therapy. Nat. Rev. Endocrinol. 2009, 5, 276–283.
    56. Sundin, A.; Arnold, R.; Baudin, E.; Cwikla, J.B.; Eriksson, B.; Fanti, S.; Fazio, N.; Giammarile, F.; Hicks, R.J.; Kjaer, A.; et al. ENETS consensus guidelines for the standards of care in neuroendocrine tumors: Radiological, nuclear medicine & hybrid imaging. Neuroendocrinology 2017, 105, 212–244.
    57. Michael Landau; Stephen Wisniewski; Jon Davison; Jejunoileal Neuroendocrine Tumors Complicated by Intestinal Ischemic Necrosis Are Associated With Worse Overall Survival. Archives of Pathology & Laboratory Medicine 2016, 140, 461-466, 10.5858/arpa.2015-0105-oa.
    58. J K Taylor; Retroperitoneal fibrosis, regional enteritis, and carcinoid tumors.. JAMA: The Journal of the American Medical Association 1971, 217, 1864, .
    59. Dominique S V M Clement; Margot E T Tesselaar; Monique E Van Leerdam; Rajaventhan Srirajaskanthan; John Ramage; Nutritional and vitamin status in patients with neuroendocrine neoplasms. World Journal of Gastroenterology 2019, 25, 1171-1184, 10.3748/wjg.v25.i10.1171.
    60. Bouma, G.; van Faassen, M.; Kats-Ugurlu, G.; de Vries, E.G.; Kema, I.P.; Walenkamp, A.M. Niacin (Vitamin B3) supplementation in patients with serotonin-producing neuroendocrine tumor. Neuroendocrinology 2016, 103, 489–494.
    61. Shah, G.M.; Shah, R.G.; Veillette, H.; Kirkland, J.B.; Pasieka, J.L.; Warner, R.R. Biochemical assessment of niacin deficiency among carcinoid cancer patients. Am. J. Gastroenterol. 2005, 100, 2307–2314.
    62. L Pantongrag-Brown; P C Buetow; N J Carr; J E Lichtenstein; J L Buck; Calcification and fibrosis in mesenteric carcinoid tumor: CT findings and pathologic correlation.. American Journal of Roentgenology 1995, 164, 387-391, 10.2214/ajr.164.2.7839976.
    63. Göran Åkerström; Per Hellman; Surgery on neuroendocrine tumours. Best Practice & Research Clinical Endocrinology & Metabolism 2007, 21, 87-109, 10.1016/j.beem.2006.12.004.
    64. Laskaratos, F.M.; Hall, A.; Alexander, S.; Stempel, C.V.; Bretherton, J.; Luong, T.V.; Watkins, J.; Ogunbiyi, O.; Toumpanakis, C.; Mandair, D.; et al. Is computed tomography an accurate diagnostic modality for the detection of mesenteric fibrosis in midgut neuroendocrine tumours? Gastroenterology 2019, 156, S-369.
    65. Laskaratos, F.-M.; Mandair, D.; Hall, A.; Alexander, S.; von Stempel, C.; Bretherton, J.; Luong, T.; Watkins, J.; Ogunbiyi, O.; Rombouts, K.; et al. Clinicopathological correlations of mesenteric fibrosis and evaluation of a novel biomarker for fibrosis detection in small bowel neuroendocrine neoplasms. Endocrine 2020.
    66. Olov Norlén; Harald Montan; Per Hellman; Peter Stålberg; Anders Sundin; Preoperative 68Ga-DOTA-Somatostatin Analog-PET/CT Hybrid Imaging Increases Detection Rate of Intra-abdominal Small Intestinal Neuroendocrine Tumor Lesions.. World Journal of Surgery 2018, 42, 498-505, 10.1007/s00268-017-4364-1.
    67. Christos Toumpanakis; Michelle K. Kim; Anja Rinke; Deidi S. Bergestuen; Christina Thirlwell; Mohid S. Khan; R. Salazar; Kjell Öberg; Combination of Cross-Sectional and Molecular Imaging Studies in the Localization of Gastroenteropancreatic Neuroendocrine Tumors. Neuroendocrinology 2014, 99, 63-74, 10.1159/000358727.
    68. Tuo Shao; Zhen Chen; Vasily Belov; Xiaohong Wang; Steve H. Rwema; Viksit Kumar; Hualong Fu; Xiaoyun Deng; Jian Rong; Qingzhen Yu; et al. [18F]-Alfatide PET imaging of integrin αvβ3 for the non-invasive quantification of liver fibrosis. Journal of Hepatology 2020, 73, 161-169, 10.1016/j.jhep.2020.02.018.
    69. Laskaratos, F.-M.; Walker, M.; Wilkins, D.; Tuck, A.; Ramakrishnan, S.; Phillips, E.; Gertner, J.; Megapanou, M.; Papantoniou, D.; Shah, R.; et al. Evaluation of clinical prognostic factors and further delineation of the effect of mesenteric fibrosis on survival in advanced midgut neuroendocrine tumours. Neuroendocrinology 2018, 107, 292–304.
    70. Rodriguez Laval, V.; Pavel, M.; Steffen, I.G.; Baur, A.D.; Dilz, L.M.; Fischer, C.; Detjen, K.; Prasad, V.; Pascher, A.; Geisel, D.; et al. Mesenteric fibrosis in midgut neuroendocrine tumors: Functionality and radiological features. Neuroendocrinology 2018, 106, 139–147.
    71. Harry De Vries; Rob T. M. Wijffels; Pax H. B. Willemse; René C. J. Verschueren; Ido P. Kema; Arend Karrenbeld; Ted R. Prins; Elisabeth G.E. De Vries; Abdominal Angina in Patients with a Midgut Carcinoid, a Sign of Severe Pathology. World Journal of Surgery 2005, 29, 1139-1142, 10.1007/s00268-005-7825-x.
    72. Kosmas Daskalakis; Andreas Karakatsanis; Ola Hessman; Heather C. Stuart; Staffan Welin; Eva Tiensuu Janson; Kjell Öberg; Per Hellman; Olov Norlén; Peter Stålberg; et al. Association of a Prophylactic Surgical Approach to Stage IV Small Intestinal Neuroendocrine Tumors With Survival.. JAMA Oncology 2018, 4, 183-189, 10.1001/jamaoncol.2017.3326.
    73. Peter E. Goretzki; Martina T. Mogl; Aycan Akca; Johann Pratschke; Curative and palliative surgery in patients with neuroendocrine tumors of the gastro-entero-pancreatic (GEP) tract. Reviews in Endocrine and Metabolic Disorders 2018, 19, 169-178, 10.1007/s11154-018-9469-9.
    74. Florian Bösch; Katharina Bruewer; Melvin D'anastasi; Harun Ilhan; Thomas Knoesel; Sebastian Pratschke; Michael Thomas; Markus Rentsch; M. Guba; J. Werner; et al. Neuroendocrine tumors of the small intestine causing a desmoplastic reaction of the mesentery are a more aggressive cohort. Surgery 2018, 164, 1093-1099, 10.1016/j.surg.2018.06.026.
    75. Piccioli, A.N.; Funicelli, L.; Fazio, N.; Borin, S.; Petz, W.; Spinoglio, G.; Bertani, E. Predicting resectability of primary tumor and mesenteric lumps in patients with small intestine neuroendocrine tumors. Neuroendocrinology 2018, 106, 283.
    76. Gonzalez, R.S.; Cates, J.M.M.; Shi, C. Number, not size, of mesenteric tumor deposits affects prognosis of small intestinal well-differentiated neuroendocrine tumors. Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. 2018, 31, 1560–1566.
    77. Lunpo Wu; Jianfei Fu; Li Wan; Jie Pan; Sanchuan Lai; Jing Zhong; Daniel C. Chung; Liangjing Wang; Survival outcomes and surgical intervention of small intestinal neuroendocrine tumors: a population based retrospective study. Oncotarget 2016, 8, 4935-4947, 10.18632/oncotarget.13632.
    78. Bruno Niederle; U.-F. Pape; F. Costa; D. Gross; F. Kelestimur; U. Knigge; K. Öberg; M. Pavel; Aurel Perren; C. Toumpanakis; et al. ENETS Consensus Guidelines Update for Neuroendocrine Neoplasms of the Jejunum and Ileum. Neuroendocrinology 2016, 103, 125-138, 10.1159/000443170.
    79. Ashley Kieran Clift; Andrea Frilling; Liver transplantation and multivisceral transplantation in the management of patients with advanced neuroendocrine tumours. World Journal of Gastroenterology 2018, 24, 2152-2162, 10.3748/wjg.v24.i20.2152.
    80. M. Pavel; K. Öberg; M. Falconi; E.P. Krenning; A. Sundin; A. Perren; A. Berruti; ESMO Guidelines Committee; Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 2020, 31, 844-860, 10.1016/j.annonc.2020.03.304.
    81. Karin H.J. Albers-Wolthers; Jeffrey De Gier; Hans S. Kooistra; Victor P.M.G. Rutten; Peter J.S. Van Kooten; Janneke J. De Graaf; Peter A.J. Leegwater; Robert P. Millar; Auke C. Schaefers-Okkens; Mark R. Palmert; et al. Abstracts of the 11th Annual ENETS Conference for the Diagnosis and Treatment of Neuroendocrine Tumor Disease, March 5-7, 2014, Barcelona, Spain: Abstracts. Neuroendocrinology 2014, 99, 219-310, 10.1159/000367792.
    82. Caplin, M.E.; Pavel, M.; Ruszniewski, P. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N. Engl. J. Med. 2014, 371, 1556–1557.
    83. Rinke, A.; Muller, H.H.; Schade-Brittinger, C.; Klose, K.J.; Barth, P.; Wied, M.; Mayer, C.; Aminossadati, B.; Pape, U.F.; Blaker, M.; et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J. Clin. Oncol. 2009, 27, 4656–4663.
    84. Joseph Davar; Heidi M. Connolly; Martyn E. Caplin; Marianne Pavel; Jerome Zacks; Sanjeev Bhattacharyya; Daniel J. Cuthbertson; Rebecca Dobson; Simona Grozinsky-Glasberg; Richard P. Steeds; et al. Diagnosing and Managing Carcinoid Heart Disease in Patients With Neuroendocrine Tumors. Journal of the American College of Cardiology 2017, 69, 1288-1304, 10.1016/j.jacc.2016.12.030.
    85. Foltyn, W.; Zemczak, A.; Rosiek, V.; Kilian-Kita, A.; Kos-Kudła, B.; Effect of Treatment with Prolonged-Release Somatostatin Analogues on the Concentration of Serum Fibrosis Markers in Patients with Carcinoid Syndrome. Neuroendocrinology 2017, 105, 197, .
    86. Ertilav, M.; Hur, E.; Bozkurt, D.; Sipahi, S.; Timur, O.; Sarsik, B.; Akcicek, F.; Duman, S. Octreotide lessens peritoneal injury in experimental encapsulated peritoneal sclerosis model. Nephrology (Carlton) 2011, 16, 552–557.
    87. Lang, A.; Sakhnini, E.; Fidder, H.H.; Maor, Y.; Bar-Meir, S.; Chowers, Y. Somatostatin inhibits pro-inflammatory cytokine secretion from rat hepatic stellate cells. Liver Int. 2005, 25, 808–816.
    88. José Mauricio Mota; Luana Guimarães Sousa; Rachel P Riechelmann; Complications from carcinoid syndrome: review of the current evidence. ecancermedicalscience 2016, 10, 662, 10.3332/ecancer.2016.662.
    89. Kulke, M.H.; Horsch, D.; Caplin, M.E.; Anthony, L.B.; Bergsland, E.; Oberg, K.; Welin, S.; Warner, R.R.; Lombard-Bohas, C.; Kunz, P.L.; et al. Telotristat ethyl, a tryptophan hydroxylase inhibitor for the treatment of carcinoid syndrome. J. Clin. Oncol. 2017, 35, 14–23.
    90. Pavel, M.; Gross, D.J.; Benavent, M.; Perros, P.; Srirajaskanthan, R.; Warner, R.R.P.; Kulke, M.H.; Anthony, L.B.; Kunz, P.L.; Horsch, D.; et al. Telotristat ethyl in carcinoid syndrome: Safety and efficacy in the TELECAST phase 3 trial. Endocr. Relat. Cancer 2018, 25, 309–322.
    91. Cristina Saavedra; Jorge Barriuso; Mairéad Geraldine McNamara; Juan W. Valle; Angela Lamarca; Spotlight on telotristat ethyl for the treatment of carcinoid syndrome diarrhea: patient selection and reported outcomes.. Cancer Management and Research 2019, 11, 7537-7556, 10.2147/CMAR.S181439.
    92. Zacks, J.; Lavine, R.; Ratner, L.; Warner, R.; Telotristat etiprate appears to halt carcinoid heart disease. Neuroendocrinology 2016, 103, 90, .
    93. Robertson, J.I. Carcinoid syndrome and serotonin: Therapeutic effects of ketanserin. Cardiovasc. Drugs Ther. 1990, 4 (Suppl 1), 53–58.
    94. Moertel, C.G.; Kvols, L.K.; Rubin, J. A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer 1991, 67, 33–36.
    95. Saurabh Chaturvedi; Durga Prasanna Misra; Narayan Prasad; Kailash Rastogi; Harshit Singh; Mohit Kumar Rai; Vikas Agarwal; 5-HT2 and 5-HT2B antagonists attenuate pro-fibrotic phenotype in human adult dermal fibroblasts by blocking TGF-β1 induced non-canonical signaling pathways including STAT3 : implications for fibrotic diseases like scleroderma. International Journal of Rheumatic Diseases 2018, 21, 2128-2138, 10.1111/1756-185x.13386.
    96. James C Yao; Nicola Fazio; Simron Singh; Roberto Buzzoni; Carlo Carnaghi; Edward Wolin; Jiri Tomasek; Markus Raderer; Harald Lahner; Maurizio Voi; et al. Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study. The Lancet 2016, 387, 968-977, 10.1016/s0140-6736(15)00817-x.
    97. Melissa A. Orr-Asman; Zhengtao Chu; Min Jiang; Mariah Worley; Kathleen LaSance; Sheryl E. Koch; Vinicius S. Carreira; Hanan M. Dahche; David R. Plas; Kakajan Komurov; et al. mTOR Kinase Inhibition Effectively Decreases Progression of a Subset of Neuroendocrine Tumors that Progress on Rapalog Therapy and Delays Cardiac Impairment. Molecular Cancer Therapeutics 2017, 16, 2432-2441, 10.1158/1535-7163.mct-17-0058.
    98. L. Lundin; I. Norheim; J. Landelius; K. Öberg; E Theodorsson; Carcinoid heart disease: relationship of circulating vasoactive substances to ultrasound-detectable cardiac abnormalities.. Circulation 1988, 77, 264-269, 10.1161/01.cir.77.2.264.
    99. Canan G. Nebigil; Jean-Marie Launay; Pierre Hickel; Claire Tournois; Luc Maroteaux; 5-Hydroxytryptamine 2B receptor regulates cell-cycle progression: Cross-talk with tyrosine kinase pathways. Proceedings of the National Academy of Sciences 2000, 97, 2591-2596, 10.1073/pnas.050282397.
    100. Kidd, M.; Schimmack, S.; Lawrence, B.; Alaimo, D.; Modlin, I.M. EGFR/TGFalpha and TGFbeta/CTGF signaling in neuroendocrine neoplasia: Theoretical therapeutic targets. Neuroendocrinology 2013, 97, 35–44.
    101. Rybinski, B.; Franco-Barraza, J.; Cukierman, E. The wound healing, chronic fibrosis, and cancer progression triad. Physiol. Genomics 2014, 46, 223–244.
    102. Chan, J.A.; Mayer, R.J.; Jackson, N.; Malinowski, P.; Regan, E.; Kulke, M.H. Phase I study of sorafenib in combination with everolimus (RAD001) in patients with advanced neuroendocrine tumors. Cancer Chemother. Pharmacol. 2013, 71, 1241–1246.
    103. Kulke, M.H.; Lenz, H.J.; Meropol, N.J.; Posey, J.; Ryan, D.P.; Picus, J.; Bergsland, E.; Stuart, K.; Tye, L.; Huang, X.; et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J. Clin. Oncol. 2008, 26, 3403–3410.
    104. Pietras, K.; Hanahan, D. A multitargeted, metronomic, and maximum-tolerated dose “chemo-switch” regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J. Clin. Oncol. 2005, 23, 939–952.
    105. Distler, O.; Gay, S. Scleroderma. Internist (Berl.) 2010, 51, 30–38.
    106. Jonathan R. Strosberg; Ghassan El-Haddad; Edward Wolin; Andrew Hendifar; James Yao; Beth Chasen; Erik Mittra; Pamela L. Kunz; Matthew H. Kulke; Heather Jacene; et al. Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors.. New England Journal of Medicine 2017, 376, 125-135, 10.1056/NEJMoa1607427.
    107. Laskaratos, F.; Cox, N.; Woo, W.L.; Khalifa, M.; Ewang, M.; Navalkissoor, S.; Quigley, A.M.; Mandair, D.; Caplin, M.; Toumpanakis, C.; et al. Assessment of changes in mesenteric fibrosis (MF) after peptide receptor radionuclide therapy (PRRT) in midgut neuroendocrine tumours (NETs). Neuroendocrinology 2019, 108, 271, .
    108. Eleanor Ager; Jaclyn Neo; C. Christophi; The renin-angiotensin system and malignancy. Carcinogenesis 2008, 29, 1675-1684, 10.1093/carcin/bgn171.
    109. Arganini, M.; Spinelli, C.; Cecchini, G.M.; Miccoli, P. Long term treatment with tamoxifen for metastatic carcinoid tumor. Acta Chir. Belg. 1989, 89, 209–211.
    110. Myers, C.F.; Ershler, W.B.; Tannenbaum, M.A.; Barth, R. Tamoxifen and carcinoid tumor. Ann. Intern. Med. 1982, 96, 383.
    111. Stathopoulos, G.P.; Karvountzis, G.G.; Yiotis, J. Tamoxifen in carcinoid syndrome. N. Engl. J. Med. 1981, 305, 52.
    112. Charles G. Moertel; Paul F. Engstrom; Allan J. Schutt; Tamoxifen Therapy for Metastatic Carcinoid Tumor: A Negative Study. Annals of Internal Medicine 1984, 100, 531, 10.7326/0003-4819-100-4-531.
    113. Mikulec, A.A.; Hanasono, M.M.; Lum, J.; Kadleck, J.M.; Kita, M.; Koch, R.J. Effect of tamoxifen on transforming growth factor beta1 production by keloid and fetal fibroblasts. Arch. Facial Plast. Surg. 2001, 3, 111–114.
    114. Dreger, N.M.; Degener, S.; Roth, S.; Ahmad-Nejad, P.; Kamper, L.; Muller, E.; von Rundstedt, F.C.; Brandt, A.S. Impact of CYP2D6 polymorphisms on tamoxifen treatment in patients with retroperitoneal fibrosis: A first step towards tailored therapy? Urology 2020, 137, 84–90.
    More